Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
Objective To quantify comparative effectiveness of interleukin (IL)−12/23 antagonist (ustekinumab), IL-17A antagonists (secukinumab and ixekizumab), PDE4 inhibitor (apremilast) and tumour necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab)...
| الحاوية / القاعدة: | RMD Open |
|---|---|
| المؤلفون الرئيسيون: | , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
BMJ Publishing Group
2021-03-01
|
| الوصول للمادة أونلاين: | https://rmdopen.bmj.com/content/7/1/e001399.full |